



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Craig Anderson et al

Serial No. : 10/079,703

Filed : February 20, 2002

For : Pharmaceutical Combination of Angiotensin II Antagonists and
Angiotensin I Converting Enzyme Inhibitors

) Art Unit : 1642

) Examiner :

) Docket No. : 1/1282

Office of Initial Patent Examination's
Customer Service Center
Washington, D.C. 20231

RECEIVED

AUG 27 2002

CORRECTION OF FILING RECEIPT

TECH CENTER 1600/2900

Sir:

The Filing Receipt for the above-identified application contains the following errors:

The last name of the first inventor should read "**Anderson**" not "Andersson".

Enclosed is a copy of the Filing Receipt with the above-mentioned correction indicated in red ink.

No fee is believed to be due at this time, however, if a fee is due, please charge Deposit Account Number 02-2955. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

David Dow
Attorney for applicant(s)
Reg. No. 46,124

I hereby certify that this correspondence is
being deposited with the U.S. Postal Service
as first class mail in an envelope addressed
to:

Assistant Commissioner for Patents
Washington, DC 20231

on July 25, 2002

By: David A. Dow
Reg. No. 46,124

COPY OF PAPERS
ORIGINALLY FILED**FILE COPY**

UNITED STATES PATENT AND TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO.	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/079,703	02/20/2002	1642	740	1/1282		10	2

CONFIRMATION NO. 7672

 28501
 BOEHRINGER INGELHEIM CORPORATION
 900 RIDGEBURY ROAD
 P. O. BOX 368
 RIDGEFIELD, CT 06877
RECEIVED

AUG 27 2002

TECH CENTER 1600/2900

FILING RECEIPT



OC000000007659875

Date Mailed: 03/18/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Anderson
 Craig Anderson, Devonport/Auckland, NEW ZEALAND;
 Salim Yusuf, Carlisle, CANADA;
 Peter Sleight, Wheatley, Oxfordshire, UNITED KINGDOM;
 Lutz Hilbrich, Wiesbaden, GERMANY;

Domestic Priority data as claimed by applicant

Foreign Applications

If Required, Foreign Filing License Granted 03/18/2002

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No



Early Publication Request: No

Title

 Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme
 inhibitors

Preliminary Class

514



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Cod , Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).